Results 191 to 200 of about 17,756 (247)

CD123-targeted therapy in acute myeloid leukemia

Expert Review of Hematology, 2021
Acute myeloid leukemia (AML) results from the neoplastic transformation of a hematopoietic stem cell. While therapeutic progress has stagnated for several decades, recent progress in the genomic classification of AML has paved the way for multiple new drug approvals.
Manuel Ricardo Espinoza-Gutarra, Steven D Green, Joshua F. Zeidner, Heiko Konig   +3 more
openaire   +2 more sources

CD123: A Novel Biomarker for Diagnosis and Treatment of Leukemia

Cardiovascular & Hematological Disorders Drug Targets, 2019
: Leukemia is a group of progressive hematologic malignancies derived from stem cells in bone marrow which causes a large number of cancer deaths. Even with treatment such as traditional chemotherapy, targeted therapy, and allogeneic stem cell transplantation (allo-HSCT), many patients suffer from relapse/refractory disease, and the overall survival ...
Mingyi Chen, Jianyu Rao
exaly   +3 more sources

Targeting CD123 in AML

Clinical Lymphoma Myeloma and Leukemia, 2020
An ideal cell surface target for therapy in leukemia would be: tumor-specific (not expressed on normal cells) or at least enriched on tumor cells, necessary for tumor but not for normal cell survival, internalized efficiently (if the surface-targeted agent is conjugated to chemotherapy or a toxin molecule), and recycled rapidly to the cell surface ...
openaire   +2 more sources

A phase II study of vibecotamab, a CD3-CD123 bispecific T-cell engaging antibody, for MRD-positive AML and MDS after hypomethylating agent failure.

Journal of Clinical Oncology, 2023
TPS7076 Background: CD123 is a marker of leukemic stem cells that is differentially overexpressed in most patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML).
N. Short, Pavan Bachireddy, Xuelin Huang, H. Hwang, Xiao-Hong Leng, Jaehyun Lee, Daniel Nguyen, G. Garcia-Manero, C. Dinardo, G. Borthakur, T. Kadia, N. Daver, G. Issa, A. Maiti, F. Ravandi   +14 more
semanticscholar   +1 more source

Hypertrophic lupus erythematosus: the diagnostic utility of CD123 staining [PDF]

Journal of Cutaneous Pathology, 2011
CD123-positive plasmacytoid dendrocytes are prominent in the infiltrate of discoid lupus erythematosus (LE). We hypothesized that these cells would also be present in hypertrophic LE and would aid in the histopathologic distinction from squamous cell carcinoma (SCC) and hypertrophic actinic keratosis (AK).
Christine Ko
exaly   +3 more sources

Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study

The Lancet Oncology
Summary Background Pivekimab sunirine (IMGN632) is a first-in-class antibody–drug conjugate comprising a high-affinity CD123 antibody, cleavable linker, and novel indolinobenzodiazepine pseudodimer payload.
N. Daver, P. Montesinos, D. DeAngelo, E. Wang, Nikolaos Papadantonakis, E. Todisco, K. Sweet, Naveen Pemmaraju, Andrew A. Lane, L. Torres-Miñana, James E. Thompson, Marina Y. Konopleva, C. Sloss, Krystal Watkins, Gaurav Bedse, Yi-Ning Du, Kara E. Malcolm, P. Zweidler-McKay, H. Kantarjian   +18 more
semanticscholar   +1 more source

IRF8 may be a useful marker for blastic plasmacytoid dendritic cell neoplasm, especially with weak CD123 expression

Journal of cutaneous pathology, 2023
We highlight the utility of interferon regulatory factor 8 (IRF8), a novel marker of monocytic and dendritic cell lineages, in the diagnosis of a case of blastic plasmacytoid dendritic cell neoplasm (BPDCN) presenting initially in the skin. A 60‐year‐old
Haiming Tang, G. Panse, D. Braddock, S. Perincheri, Mina L. Xu, J. McNiff   +5 more
semanticscholar   +1 more source

The CD123 antibody–drug conjugate pivekimab sunirine exerts profound activity in preclinical models of pediatric acute lymphoblastic leukemia

HemaSphere
Antibody–drug conjugates (ADCs) combining monoclonal antibodies with cytotoxic payloads are a rapidly emerging class of immune‐based therapeutics with the potential to improve the treatment of cancer, including children with relapse/refractory acute ...
Ben Watts, Christopher M. Smith, K. Evans, Andrew J. Gifford, S. M. Mohamed, S. Erickson, E. Earley, Steven B. Neuhauser, T. Stearns, Vivek M Philip, Jeffrey H. Chuang, P. Zweidler-McKay, S. Lakshmikanthan, E. Jocoy, C. Bult, Beverly A. Teicher, Malcolm A. Smith, Richard B. Lock   +17 more
semanticscholar   +1 more source

Potent in Vitro and In Vivo Efficacy of BYON4413, a Duba-Based Antibody-Drug Conjugate Targeting CD123 in Acute Myeloid Leukemia

Blood, 2023
Acute myeloid leukemia (AML) and myelodysplasia (MDS) result from a differentiation impairment driving an accumulation of immature myeloid cells in the bone marrow and peripheral blood.
Miranda M. C. Van der Lee, Tanja van Achtenberg, A. Brouwers-Vos, M. V. D. Van der Vleuten, Wendy Kappers, G. Verheijden, G. Huls, G. V. van Wigcheren, R. Ubink, Aloys Sesink, Alyson MacInnes, J. Schuringa, W. Dokter   +12 more
semanticscholar   +1 more source

Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML

Blood
Background Leukemic stem cells have high expression of CD123 compared to normal hematopoietic stem cells. CD123 is therefore an attractive therapeutic target in myeloid neoplasms including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS),
Daniel Nguyen, F. Ravandi, Sa A. Wang, J. Jorgensen, Wei Wang, S. Loghavi, Jaehyun Lee, Pavan Bachireddy, C. Dinardo, K. Chien, G. Montalban-Bravo, G. Issa, A. Maiti, Yesid Alvarado Valero, N. Daver, E. Jabbour, T. Kadia, Naveen Pemmaraju, M. Yilmaz, Daniel Nguyen, U. Popat, E. Shpall, G. Garcia-Manero, H. Kantarjian, N. Short   +24 more
semanticscholar   +1 more source